Iron inhibits neurotoxicity induced by trace copper and biological reductants

Publisher Website
Google Scholar
Abstract
The extracellular microenvironment of the brain contains numerous biological redox agents, including ascorbate, glutathione, cysteine and homocysteine. During ischemia/reperfusion, aging or neurological disease, extracellular levels of reductants can increase dramatically owing to dysregulated homeostasis. The extracellular concentrations of transition metals such as copper and iron are also substantially elevated during aging and in some neurodegenerative disorders. Increases in the extracellular redox capacity can potentially generate neurotoxic free radicals from reduction of Cu(II) or Fe(III), resulting in neuronal cell death. To investigate this in vitro, the effects of extracellular reductants (ascorbate, glutathione, cysteine, homocysteine or methionine) on primary cortical neurons was examined. All redox agents except methionine induced widespread neuronal oxidative stress and subsequent cell death at concentrations occurring in normal conditions or during neurological insults. This neurotoxicity was totally dependent on trace Cu (≥0.4 μM) already present in the culture medium and did not require addition of exogenous Cu. Toxicity involved generation of Cu(I) and H2O2, while other trace metals did not induce toxicity. Surprisingly, administration of Fe(II) or Fe(III) (≥2.5 μM) completely abrogated reductant-mediated neurotoxicity. The potent protective activity of Fe correlated with Fe inhibiting reductant-mediated Cu(I) and H2O2 generation in cell-free assays and reduced cellular Cu uptake by neurons. This demonstrates a novel role for Fe in blocking Cu-mediated neurotoxicity in a high reducing environment. A possible pathogenic consequence for these phenomena was demonstrated by abrogation of Fe neuroprotection after pre-exposure of cultures to the Alzheimer’s amyloid beta peptide (Aβ). The loss of Fe neuroprotection against reductant toxicity was greater after treatment with human Aβ1–42 than with human Aβ1–40 or rodent Aβ1–42, consistent with the central role of Aβ1–42 in Alzheimer’s disease. These findings have important implications for trace biometal interactions and free radical-mediated damage during neurodegenerative illnesses such as Alzheimer’s disease and old-age dementia.